argenx (ARGX) Competitors $649.09 +13.07 (+2.05%) Closing price 04:00 PM EasternExtended Trading$648.88 -0.21 (-0.03%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARGX vs. SNY, GSK, TAK, BNTX, ONC, TEVA, BGNE, SMMT, ITCI, and VTRSShould you be buying argenx stock or one of its competitors? The main competitors of argenx include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. argenx vs. Sanofi GSK Takeda Pharmaceutical BioNTech Beigene Teva Pharmaceutical Industries BeiGene Summit Therapeutics Intra-Cellular Therapies Viatris argenx (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability. Which has higher valuation and earnings, ARGX or SNY? Sanofi has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioargenx$1.27B31.09-$295.05M-$0.88-737.60Sanofi$44.29B3.13$6.22B$2.4921.91 Do insiders and institutionals hold more shares of ARGX or SNY? 60.3% of argenx shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor ARGX or SNY? In the previous week, argenx had 3 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for argenx and 16 mentions for Sanofi. Sanofi's average media sentiment score of 1.25 beat argenx's score of 0.95 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenx 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ARGX or SNY? argenx received 597 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 67.19% of users gave argenx an outperform vote while only 60.98% of users gave Sanofi an outperform vote. CompanyUnderperformOutperformargenxOutperform Votes64767.19% Underperform Votes31632.81% SanofiOutperform Votes5060.98% Underperform Votes3239.02% Is ARGX or SNY more profitable? Sanofi has a net margin of 12.77% compared to argenx's net margin of -2.11%. Sanofi's return on equity of 25.58% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets argenx-2.11% -1.45% -1.29% Sanofi 12.77%25.58%14.70% Do analysts prefer ARGX or SNY? argenx presently has a consensus price target of $658.39, suggesting a potential upside of 1.43%. Sanofi has a consensus price target of $60.00, suggesting a potential upside of 9.97%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenx 1 Sell rating(s) 2 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.86Sanofi 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more volatility and risk, ARGX or SNY? argenx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. SummarySanofi beats argenx on 11 of the 19 factors compared between the two stocks. Get argenx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.44B$3.06B$5.68B$9.04BDividend YieldN/A1.79%5.32%4.00%P/E Ratio-737.6047.1990.0319.29Price / Sales31.09326.101,032.0475.93Price / CashN/A192.7646.0938.87Price / Book9.383.975.085.00Net Income-$295.05M-$40.60M$113.38M$222.75M7 Day Performance-3.37%-4.58%-1.00%-0.55%1 Month Performance-1.09%-0.97%4.22%3.03%1 Year Performance65.29%-9.78%21.48%17.92% argenx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenx2.5468 of 5 stars$649.09+2.1%$658.39+1.4%+58.4%$39.44B$1.27B-737.601,148Positive NewsSNYSanofi4.1636 of 5 stars$53.44+0.2%$60.00+12.3%+15.9%$135.62B$44.46B21.4686,088Positive NewsGSKGSK3.3105 of 5 stars$36.52+1.3%$43.25+18.4%-13.9%$75.66B$40.10B22.9670,200Earnings ReportDividend IncreaseAnalyst ForecastTAKTakeda Pharmaceutical3.1421 of 5 stars$13.47-0.5%N/A-5.7%$42.84B$28.20B33.6649,281BNTXBioNTech3.069 of 5 stars$115.73-1.6%$142.72+23.3%+22.9%$27.72B$4.13B-55.076,133ONCBeigeneN/A$220.50-1.3%N/AN/A$21.55B$2.46B-26.7610,600Analyst RevisionNews CoveragePositive NewsTEVATeva Pharmaceutical Industries2.7494 of 5 stars$16.66-1.0%$23.57+41.5%+38.4%$18.87B$16.54B-11.4937,851Short Interest ↑BGNEBeiGene1.5119 of 5 starsN/A$253.69+∞N/A$18.03B$3.32B-22.429,000Analyst ForecastSMMTSummit Therapeutics2.4213 of 5 stars$20.53+2.1%$33.57+63.5%+324.0%$15.15B$700,000.00-73.35110ITCIIntra-Cellular Therapies3.945 of 5 stars$127.08+0.1%$103.62-18.5%+75.3%$13.51B$612.78M-146.09560Short Interest ↑VTRSViatris3.2185 of 5 stars$10.72-0.1%$13.67+27.5%-9.2%$12.78B$15.43B-14.4738,000 Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives BNTX Alternatives ONC Alternatives TEVA Alternatives BGNE Alternatives SMMT Alternatives ITCI Alternatives VTRS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARGX) was last updated on 2/12/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored$589 billion wiped out overnightYou need to watch this before you invest another cent in AI. Because more than $589 billion was wiped out o...Porter & Company | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.